본문 바로가기
KERD
논문KCI 등재

Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”

Kim Hyo-Soo|Kang Jeehoon|Park Kyung Woo|전원경
한국지질동맥경화학회 (The Korean Society of Lipidology and Atherosclerosis)|2022.01|지질·동맥경화학회지 (Journal of Lipid and Atherosclerosis)|제11권 제1호|pp. 89-101|DOI 10.12997/jla.2022.11.1.89

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Diabetes mellitusCardiovascular riskSulfonylurea compoundsDPP4 inhibitor

초록

Objective: Recent studies have raised concerns about the cardiovascular safety of dipeptidyl peptidase-4 (DPP4) inhibitors. We performed a systematic review and meta-analysis to compare the cardiovascular outcomes of sulfonylureas (SUs) versus DPP4 inhibitors in combination with metformin. Methods: After searching for trials using combination therapy of metformin with an SU or DPP4 inhibitor in PubMed, Cochrane Library, and Embase, 1 prospective observational study and 15 randomized controlled studies were selected. Results: Regarding the primary analysis endpoint, no significant differences were found in the risk of all-cause mortality between SUs and DPP4 inhibitors as add-on therapies to metformin (random-effect relative risk [RR], 1.14; 95% confidence interval [CI], 0.98–1.33; I2=0%; p=0.097). Cardiovascular death was also similar between SUs and DPP4 inhibitors in the 5 studies that reported outcomes (random-effect RR, 1.03; 95% CI, 0.83–1.27; I2=0%; p=0.817). Furthermore, there were no significant differences in major adverse cardiac events, coronary heart disease, myocardial infarction, and heart failure. However, the SU group showed a higher risk of ischemic stroke, more hypoglycemic events, and more weight gain than the DPP4 inhibitor group (ischemic stroke, random-effect RR, 2.78; 95% CI, 1.06–7.30; I2=51.9%; p=0.039; hypoglycemia, random-effect RR, 3.79; 95% CI, 1.53–9.39; I2=98.2; p=0.004; weight gain, weighted mean difference, 1.68; 95% CI, 1.07–2.29; I2=94.7; p<0.001). Conclusion: As add-on therapies to metformin, SUs and DPP4 inhibitors showed no significant differences in all-cause mortality and cardiovascular mortality. However, some of the favorable results of DPP4 inhibitors suggest good safety and feasibility of the drugs.

Abstract

Objective: Recent studies have raised concerns about the cardiovascular safety of dipeptidyl peptidase-4 (DPP4) inhibitors. We performed a systematic review and meta-analysis to compare the cardiovascular outcomes of sulfonylureas (SUs) versus DPP4 inhibitors in combination with metformin. Methods: After searching for trials using combination therapy of metformin with an SU or DPP4 inhibitor in PubMed, Cochrane Library, and Embase, 1 prospective observational study and 15 randomized controlled studies were selected. Results: Regarding the primary analysis endpoint, no significant differences were found in the risk of all-cause mortality between SUs and DPP4 inhibitors as add-on therapies to metformin (random-effect relative risk [RR], 1.14; 95% confidence interval [CI], 0.98–1.33; I2=0%; p=0.097). Cardiovascular death was also similar between SUs and DPP4 inhibitors in the 5 studies that reported outcomes (random-effect RR, 1.03; 95% CI, 0.83–1.27; I2=0%; p=0.817). Furthermore, there were no significant differences in major adverse cardiac events, coronary heart disease, myocardial infarction, and heart failure. However, the SU group showed a higher risk of ischemic stroke, more hypoglycemic events, and more weight gain than the DPP4 inhibitor group (ischemic stroke, random-effect RR, 2.78; 95% CI, 1.06–7.30; I2=51.9%; p=0.039; hypoglycemia, random-effect RR, 3.79; 95% CI, 1.53–9.39; I2=98.2; p=0.004; weight gain, weighted mean difference, 1.68; 95% CI, 1.07–2.29; I2=94.7; p<0.001). Conclusion: As add-on therapies to metformin, SUs and DPP4 inhibitors showed no significant differences in all-cause mortality and cardiovascular mortality. However, some of the favorable results of DPP4 inhibitors suggest good safety and feasibility of the drugs.

참고문헌 (46)

  1. American Diabetes Association, "Standards of medical care in diabetes--2010", Diabetes Care, 33(Suppl 1), pp.S11~S61 (2010)
  2. Nathan DM, "Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 32, pp.193~203 (2009)
  3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction", Can J Diabetes, 37(Suppl 1), pp.S1~S3 (2013)
  4. International Diabetes Federation Guideline Development Group, "Global guideline for type 2 diabetes", Diabetes Res Clin Pract, 104, pp.1~52 (2014)
  5. Bennett WL, "Comparative effectiveness and safety of medications for type 2 diabetes : an update including new drugs and 2-drug combinations", Ann Intern Med, 154, pp.602~613 (2011)
  6. Warren RE, "The stepwise approach to the management of type 2 diabetes", Diabetes Res Clin Pract, 65(Suppl 1), pp.S3~S8 (2004)
  7. Chan JC, "Role of metformin in the initiation of pharmacotherapy for type 2 diabetes : an Asian-Pacific perspective", Diabetes Res Clin Pract, 75, pp.255~266 (2007)
  8. Consoli A, "Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients : an evidence-based strategy to reduce the burden of late-developing diabetes complications", Diabetes Metab, 30, pp.509~516 (2004)
  9. Davies MJ, "Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)", Diabetes Care, 41, pp.2669~2701 (2018)
  10. Deacon CF, "Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes : comparison, efficacy and safety", Expert Opin Pharmacother, 14, pp.2047~2058 (2013)
  11. Scheen AJ, "DPP-4 inhibitors in the management of type 2 diabetes : a critical review of head-to-head trials", Diabetes Metab, 38, pp.89~101 (2012)
  12. Gallwitz B, "Clinical use of DPP-4 inhibitors", Front Endocrinol(Lausanne), 10, pp.389~ (2019)
  13. Monami M, "Dipeptidyl peptidase-4 inhibitors and heart failure : a metaanalysis of randomized clinical trials", Nutr Metab Cardiovasc Dis, 24, pp.689~697 (2014)
  14. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
  15. Inzucchi SE, "Management of hyperglycemia in type 2 diabetes, 2015 : a patient-centered approach : update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 38, pp.140~149 (2015)
  16. Bailey T, "Options for combination therapy in type 2 diabetes : comparison of the ADA", EASD position statement and AACE, Am J Med, pp.2013, 126[DOI]
  17. Gitt AK, "Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting-results of the 1 year follow-up of the prospective DiaRegis registry", Int J Clin Pract, 67, pp.1005~1014 (2013)
  18. Arjona Ferreira JC, "Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis : a 54-week randomized trial", Am J Kidney Dis, 61, pp.579~587 (2013)
  19. Del Prato S, "Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus : a 2-year study", Diabetes Obes Metab, 16, pp.1239~1246 (2014)
  20. Ferrannini E, "Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy", Diabetes Obes Metab, 11, pp.157~166 (2009)
  21. Filozof C, "A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone : a 52-week, randomized study", Diabet Med, 27, pp.318~326 (2010)
  22. Foley JE, "Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes", Horm Metab Res, 41, pp.905~909 (2009)
  23. Gallwitz B, "2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin : a randomised, double-blind, non-inferiority trial", Lancet, 380, pp.475~483 (2012)
  24. Göke B, "Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone : long-term(52-week)extension of a 52-week randomised controlled trial", Int J Clin Pract, 67, pp.307~316 (2013)
  25. Laakso M, "Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2diabetes with moderate to severe renal impairment : a 52-week, randomized, double-blind clinical trial", Diabetes Care, 38, pp.e15~e17 (2015)
  26. Matthews DR, "Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain : results from a 2-year study", Diabetes Obes Metab, 12, pp.780~789 (2010)
  27. Rosenstock J, "Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia : a prospective, double-blind, randomized, 1-year study", Diabetes Obes Metab, 15, pp.906~914 (2013)
  28. Schernthaner G, "Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes : a randomized, controlled study(GENERATION)", Diabetes Obes Metab, 17, pp.630~638 (2015)
  29. Seck T, "Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin : a 2-year study", Int J Clin Pract, 64, pp.562~576 (2010)
  30. Arjona Ferreira JC, "Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency", Diabetes Care, 36, pp.1067~1073 (2013)
  31. Rosenstock J, "Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes : the CAROLINA randomized clinical trial", JAMA, 322, pp.1155~1166 (2019)
  32. Zhang Y, "Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas-a meta-analysis from randomized clinical trials", Diabetes Metab Res Rev, 30, pp.241~256 (2014)
  33. Rosenstock J, "Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk : the CARMELINA randomized clinical trial", JAMA, 321, pp.69~79 (2019)
  34. McGuire DK, "Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA", Circulation, 139, pp.351~361 (2019)
  35. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
  36. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
  37. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
  38. Bain S, "Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs : a Bayesian meta-analysis of survival data", Diabetes Obes Metab, 19, pp.329~335 (2017)
  39. Azoulay L, "Sulfonylureas and the risks of cardiovascular events and death : a methodological meta-regression analysis of the observational studies", Diabetes Care, 40, pp.706~714 (2017)
  40. Palmer SC, "Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes : a meta-analysis", JAMA, 316, pp.313~324 (2016)
  41. Darsalia V, "Dipeptidyl peptidase-4 inhibitors for the potential treatment of brain disorders; a mini-review with special focus on linagliptin and stroke", Front Neurol, 10, pp.493~ (2019)
  42. Wang F, "Combination therapy of metformin plus dipeptidyl peptidase-4inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients", Medicine(Baltimore), 96, pp.e7638~ (2017)
  43. Monami M, "Cardiovascular safety of sulfonylureas : a meta-analysis of randomized clinical trials", Diabetes Obes Metab, 15, pp.938~953 (2013)
  44. Lee G, "Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity : a network meta-analysis", PLoS One, 12, pp.e0177646~ (2017)
  45. Chou CY, "Effect of long-term incretin-based therapies on ischemic heart diseases in patients with type 2 diabetes mellitus : a network meta-analysis", Sci Rep, 7, pp.15795~ (2017)
  46. Wu S, "The cardiovascular effect of incretin-based therapies among type 2 diabetes : a systematic review and network meta-analysis", Expert Opin Drug Saf, 17, pp.243~249 (2018)

관련 논문AI추천

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis강지훈, 김효수, 박경우, 전원경한국지질동맥경화학회 · 지질·동맥경화학회지2021 · 제10권 제2호Response to Letter Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis”Park Kyung Woo한국지질동맥경화학회 · 지질·동맥경화학회지2022 · 제11권 제1호제2형 당뇨병 환자에서 Metformin/Dipeptidyl Peptidase-4 저해제 병용요법과 Metformin/Sulfonylurea 병용요법간의 효과에 대한 비교 연구곽혜선, 김재연, 김주희, 박선이, 박지혜한국임상약학회 · 한국임상약학회지2015 · 제25권 제2호Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes강은석, 김영은, 배재현, 이민영, 이병완, 이용호, 차봉수연세대학교의과대학 · Yonsei Medical Journal2022 · 제63권 제6호Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)정인경한국지질동맥경화학회 · 지질·동맥경화학회지2018 · 제7권 제1호Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis”Singh Awadhesh Kumar, Singh Ritu한국지질동맥경화학회 · 지질·동맥경화학회지2022 · 제11권 제1호

이 간행물의 다른 논문 (7건)

SGLT2 Inhibitors and Ketone Metabolism in Heart FailureWestenbrink B. Daan, Yurista Salva R., de Boer Rudolf A., Voorrips Suzanne N., Saucedo-Orozco Huitzilihuitlpp. 1-19Metabolism and Health Impacts of Dietary SugarsKim Raymond, Jang Cholsoon, Alam Yasmine Hennapp. 20-38Individualized Treatment for Patients With Familial HypercholesterolemiaTada Hayato, Takamura Masayuki, Kawashiri Masa-akipp. 39-54Profiling of RNA-binding Proteins Interacting With Glucagon and Adipokinetic Hormone mRNAsYoon Je-Hyun, Lee Kyu-Sun, Delaney Joe R., Chun Yoo Lim, Mun Hyejin, Howard-McGuire Marina, Millison Nathan T., Lee Kwang-Pyo, Lee Changhan, Ko Seungbeom, 정준양, 염은별pp. 55-72Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based StudyHan Kyungdo, 박철영, 김경수, Hong Sangmopp. 73-83
원문 보기